Modality
Degrader
MOA
IL-17i
Target
AHR
Pathway
mTOR
MCLBCCPompe
Development Pipeline
Preclinical
Dec 2017
→ Aug 2029
PreclinicalCurrent
NCT03851217
1,521 pts·BCC
2017-12→2029-08·Terminated
NCT06398297
2,738 pts·MCL
2024-05→2027-12·Completed
4,259 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-12-261.7y awayInterim· MCL
2029-08-153.4y awayInterim· BCC
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Preclinical
Termina…
Preclinical
Complet…
Catalysts
Interim
2027-12-26 · 1.7y away
MCL
Interim
2029-08-15 · 3.4y away
BCC
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03851217 | Preclinical | BCC | Terminated | 1521 | NT-proBNP |
| NCT06398297 | Preclinical | MCL | Completed | 2738 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Doxalemzoparlimab | Nuvalent | Approved | AHR |